---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-074130"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:30:06.846161+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics raises $100M in registered direct offering to fund pipeline

## Summary
- Gross proceeds of $100M from sale of 3,367,003 shares at $14.85 and pre-funded warrants at $14.8499.
- Offering led by U.S. healthcare-focused investor, two global mutual funds, and Janus Henderson.
- Proceeds to fund Phase 2b trials for ENTR-601-44/45 and Phase 2 MAD trial for ENTR-601-50.
- Expected closing on June 25, 2024; cash runway extended into 2027.
- 30-day lockup on new equity issuance and registration statements.

## SEC filing metadata
- accession: 0001104659-24-074130
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465924074130/0001104659-24-074130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465924074130/tm2417848d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-074130
- JSON: https://secwatch.observer/filing/0001104659-24-074130.json
- Plain text: https://secwatch.observer/filing/0001104659-24-074130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.